DUBLIN, Sept. 26, 2017 /PRNewswire/ -- Today, Allergan plc (NYSE: AGN) is pleased to announce that ACZONE ® (dapsone) Gel, 7.5%, a prescription medicine used on the skin (topical) to treat acne in ...
Launch continues the expansion of Cosette’s generic portfolio and global partnership strategy BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc. (“Cosette”), in partnership with ...
The FINANCIAL — Allergan plc on February 25 announced that the Company has received approval from the U.S. Food and Drug Administration (FDA) to market ACZONE (dapsone) Gel, 7.5%, a new prescription ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. By week 24, the number of lesions decreased by 53% from ...
Feb. 22, 2005 (New Orleans) -- A new topical gel containing 5% dapsone is showing promise in the treatment of acne vulgaris, according to results from two studies reported here at the 63rd annual ...
The Food and Drug Administration (FDA) has approved Aczone (dapsone; Almirall) Gel 7.5% for the topical treatment of acne vulgaris in patients aged ≥9 years. Previously, the treatment had been ...
Aczone is the only acne treatment to harness the potential of dapsone in a topical formulation to provide patients with a convenient and effective therapy. QLT USA owns worldwide marketing rights to ...
Active ingredient: Dapsone 5%; gel. Indication: Topical treatment of acne vulgaris. Pharmacology: Dapsone is an antibacterial agent that is used systemically to treat infections such as leprosy and ...
July 14, 2005 -- The U.S. Food and Drug Administration (FDA) has approved isosorbide dinitrate/hydralazine HCl tablets for use in self-identified black patients as an adjunct to standard heart failure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback